Overview

Phase III Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia

Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
This study is to determine whether once-per-cycle DA-3031(PEG-G-CSF) is not inferior to daily G-CSF in chemotherapy-induced neutropenia.
Phase:
Phase 3
Details
Lead Sponsor:
Dong-A ST Co., Ltd.
Treatments:
Lenograstim